PRIMARY STUDY
Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia
Key Findings: Resulting data revealed that treatment with Beta-Caryophyllene (BCP), CBD, and their combination was associated with a significant decrease in infarct size.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): United States
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB2
Dosage: Beta-Caryophyllene (BCP) (3–30 mg/kg IP) and CBD (3–30 mg/kg IP), given alone or in combination (30:3, 30:10, and 30:30 BCP:CBD)
Route of Administration: Injection
Link to study
